China SXT Pharmaceuticals Stock Set to Reverse Split on Monday, August 10th (NASDAQ:SXTC)

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) are scheduled to reverse split on Monday, August 10th. The 1-80 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 9th.

China SXT Pharmaceuticals Stock Down 19.6%

China SXT Pharmaceuticals stock traded down $0.01 during mid-day trading on Thursday, hitting $0.05. 46,705,100 shares of the company’s stock traded hands, compared to its average volume of 112,669,208. The firm has a 50 day moving average price of $1.76 and a 200 day moving average price of $2.66. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a one year low of $0.05 and a one year high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC lifted its position in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the period. XTX Topco Ltd acquired a new position in shares of China SXT Pharmaceuticals during the 4th quarter valued at $36,000. Finally, Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals during the 3rd quarter valued at $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.